EGFR and non-small cell lung carcinoma: This allowed us to assess the spectrum of actionable genomic alterations in general—and EGFR genomic alterations in particular—in 1961 consecutive NSCLC cases, 513 (26.2%) and 1448 (73.8%) of which were classified as early and advanced stage, respectively.